Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sleijfer

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Clinical Pharmacology and Therapeutics|March 21, 2014
"It's the economy, stupid": strategies for improved cost containment in cancer treatmentS Sleijfer
Chest|August 15, 2001
Bleomycin-induced pneumonitisS Sleijfer
Clinical Pharmacology and Therapeutics|January 20, 2009
The price of success: cost-effectiveness of molecularly targeted agentsS Sleijfer, J Verweij
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
Physical activity in long-term survivors of germ-cell cancerS Sleijfer, R de Wit
The Netherlands Journal of Medicine|August 15, 2003
Aplastic anaemia: a reviewS Sleijfer, P J Lugtenburg
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1994
Tumour necrosis factor: the decline and fall of a biological agent and its resurrectionS Sleijfer, N H Mulder
European Journal of Cancer (Oxford, England : 1990)|December 29, 2007
The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator?A Jager, S Sleijfer, C C D van der Rijt
Cancer Treatment Reviews|May 21, 2013
Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristicsW Onstenk, J W Gratama, J A Foekens, et al.
The Netherlands Journal of Medicine|March 1, 1996
Successful treatment on an out-patient basis of a patient with Down's syndrome and disseminated testicular seminomaS Sleijfer, H S Koops, W T van der Graaf
International Journal of Cancer|June 25, 1998
Enhanced sensitivity to tumor necrosis factor-alpha in doxorubicin-resistant tumor cell lines due to down-regulated c-erbB2S Sleijfer, J G Asschert, H Timmer-Bosscha, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Clinical Pharmacology and Therapeutics|March 21, 2014
"It's the economy, stupid": strategies for improved cost containment in cancer treatmentS Sleijfer
Chest|August 15, 2001
Bleomycin-induced pneumonitisS Sleijfer
Clinical Pharmacology and Therapeutics|January 20, 2009
The price of success: cost-effectiveness of molecularly targeted agentsS Sleijfer, J Verweij
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
Physical activity in long-term survivors of germ-cell cancerS Sleijfer, R de Wit
The Netherlands Journal of Medicine|August 15, 2003
Aplastic anaemia: a reviewS Sleijfer, P J Lugtenburg
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1994
Tumour necrosis factor: the decline and fall of a biological agent and its resurrectionS Sleijfer, N H Mulder
European Journal of Cancer (Oxford, England : 1990)|December 29, 2007
The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator?A Jager, S Sleijfer, C C D van der Rijt
Cancer Treatment Reviews|May 21, 2013
Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristicsW Onstenk, J W Gratama, J A Foekens, et al.
The Netherlands Journal of Medicine|March 1, 1996
Successful treatment on an out-patient basis of a patient with Down's syndrome and disseminated testicular seminomaS Sleijfer, H S Koops, W T van der Graaf
International Journal of Cancer|June 25, 1998
Enhanced sensitivity to tumor necrosis factor-alpha in doxorubicin-resistant tumor cell lines due to down-regulated c-erbB2S Sleijfer, J G Asschert, H Timmer-Bosscha, et al.
Pageof 10